In mid-January 2024, the Friedrich Schiller University Jena made an important discovery public: A team of researchers from the universities of Jena and Shenzhen (China), as well as the Jena University Hospital, decoded a molecular mechanism that plays a crucial role in the development of breast cancer.
UK relies on EMA’s review of Xgeva reformulation in first-ever reciprocal approval
For the first time since Brexit, the UK’s medicines regulator has made use of its new approval pathway that can speed drug approvals based on
March 2, 2024